NEOK Bio, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
NEOK Bio, Inc. - overview
Established
2025
Location
Palo Alto, CA, US
Primary Industry
Biotechnology
About
NEOK Bio, Inc. is a biotechnology company dedicated to advancing innovative bispecific antibody-drug conjugates (ADCs) that improve cancer treatment precision and efficacy, targeting solid tumors with significant unmet medical needs. Founded in 2025 in Palo Alto, US, NEOK Bio, Inc. focuses on the development of bispecific ADCs for oncology.
In November 2025, NEOK Bio, Inc. raised USD 75million in venture funding from ABL Bio, Inc. NEOK Bio specializes in developing bispecific antibody-drug conjugates (ADCs) designed to revolutionize cancer treatment. Their dual-targeting strategy enhances the efficacy of cancer therapies, specifically addressing the challenges of traditional ADCs.
These products are aimed at targeting solid tumors with unmet medical needs and are primarily marketed to oncologists and healthcare providers across North America, Europe, and Asia, where demand for innovative cancer therapeutics is high. NEOK Bio generates revenue through strategic partnerships and collaborations with healthcare providers and organizations in oncology. Their business model includes the development and commercialization of bispecific ADCs, typically offered to medical institutions and biopharma partners under negotiated agreements. Revenue may arise from partnerships involving shared research and development costs or licensing agreements for their ADC technologies.
The company aims to fulfill the treatment needs of cancer patients, thereby driving adoption among healthcare professionals. With the recent venture funding of USD 75 mn from ABL Bio, Inc. on November 4, 2025, NEOK Bio plans to accelerate the development and launch of new bispecific ADC products aimed at solid tumors. The company is targeting expansion into additional markets in Europe and Asia by late 2026, focusing on regions with high demand for advanced cancer therapeutics.
This funding will support their research initiatives and market entry strategies, enhancing their capabilities to deliver innovative treatments to healthcare providers.
Current Investors
ABL Bio, Inc.
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Molecular Science, Genetics & Gene Therapy, Oncology/Cancer Treatment
Website
www.neokbio.com
Company Stage
Series A
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.